GSK to start Phase 3 trial of mRNA flu vaccine after strong mid-stage results

GSK announced it will begin a Phase 3 trial of its mRNA-based influenza vaccine, with enrollment slated to start in September.

In a Phase 2 study of 971 adults, the investigational vaccine, which targets two primary flu antigens, generated higher immune responses than standard inactivated flu shots in both younger and older participants.

The study also reported that the vaccine was generally well tolerated across the trial population.

The launch comes shortly after the FDA approved Moderna's mFLUVISA, the first mRNA flu vaccine in the United States, highlighting growing confidence in the mRNA platform for seasonal influenza.